EAT Thickness as a Predominant Feature for Evaluating Arterial Stiffness in Patients with Heart Failure with Preserved Ejection Fraction

Diabetes Metab Syndr Obes. 2022 Apr 21:15:1217-1226. doi: 10.2147/DMSO.S356001. eCollection 2022.

Abstract

Objective: Heart failure with preserved ejection fraction (HFpEF) is an intricacy heterogeneous syndrome. However, the association between EAT and arterial stiffness in HFpEF patients remains unknown.

Methods: A total of 102 patients were enrolled into the study, and brachial-ankle pulse-wave velocity (baPWV), epicardial adipose tissue (EAT) and body composition were assessed. Linear regression analysis was carried out to model the relationship between variables (especially EAT thickness) and baPWV.

Results: The results showed that patients with the thicker EAT fat pad (≥3.55 mm) tended to have comorbidities of hypertension, coronary artery disease (CAD), diabetes and hyperlipidemia, also with a higher level of obesity, fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC) and triglyceride (TG). The level of baPWV was higher in EAT ≥3.55 mm group than the other group. BaPWV was positively associated with EAT, age, heart rate, waist circumference, visceral fat area, systolic and diastolic blood pressure, CRP and FBG. After adjusting for EAT, age and visceral fat area, EAT thickness (β = 0.256, P = 0.009) and visceral fat area (β = 0.229, P = 0.036) significantly associated with baPWV.

Conclusion: The study assessed for the first time that the increased EAT thickness was closely related with baPWV in HFpEF patients, suggesting patients with the thicker EAT may be independently associated with arterial stiffness under the context of HFpEF.

Keywords: HFpEF; artery stiffness; baPWV; epicardial adipose tissue.

Publication types

  • Case Reports
  • Clinical Trial

Grants and funding

Coauthor Z.D. was funded by National Natural Science Foundation of China, 81570212; Chongqing Health Commission, 2022MSXM028; Chongqing Returnees Stay and Create Fund 2020, Chongqing High-end Talent Fund. Coauthor G.L. was funded by China Cardiovascular Health Alliance-Access Research Fund (2021-CCA-ACCESS-130).